Key Insights

Highlights

Success Rate

75% trial completion

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 39/100

Termination Rate

6.1%

2 terminated out of 33 trials

Success Rate

75.0%

-11.5% vs benchmark

Late-Stage Pipeline

21%

7 trials in Phase 3/4

Results Transparency

50%

3 of 6 completed with results

Key Signals

3 with results75% success

Data Visualizations

Phase Distribution

31Total
Not Applicable (3)
Early P 1 (1)
P 1 (16)
P 2 (4)
P 3 (3)
P 4 (4)

Trial Status

Recruiting13
Completed6
Not Yet Recruiting4
Unknown3
Active Not Recruiting3
Withdrawn2

Trial Success Rate

75.0%

Benchmark: 86.5%

Based on 6 completed trials

Clinical Trials (33)

Showing 20 of 20 trials
NCT06072482Phase 4RecruitingPrimary

A Study to Evaluate Avacopan in Participants With ANCA-associated Vasculitis

NCT07160608Phase 2RecruitingPrimary

Safety and Efficacy of Tarperprumig in Adult Participants With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis

NCT06733935Phase 1Recruiting

A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)

NCT03323476Phase 3Active Not RecruitingPrimary

Maintaining or Stopping Immunosuppressive Therapy in Patients With ANCA Vasculitis and End-stage Renal Disease

NCT07236762Phase 1Recruiting

An Exploratory Clinical Study of YTS109 Cell for R/R Autoimmune Diseases

NCT07236801Phase 1Recruiting

Exploratory Clinical Study on YTS109 Cell Therapy for Autoimmune Diseases

NCT07104721Phase 1Recruiting

A Clinical Study of YTS109 Cell for R/R Autoimmune Diseases

NCT07123519Phase 1Recruiting

A Clinical Study of YTS109 Cells for the Treatment of R/R Autoimmune Diseases

NCT07246096Early Phase 1Recruiting

Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA U CAR-T Cell Injection for the Treatment of Relapsed/Refractory Autoimmune Diseases

NCT07388277Phase 1Not Yet RecruitingPrimary

CC-97540 in Patients With Antineutrophil Cytoplasmic Antibody-associated Vasculitis

NCT07212322Not ApplicableNot Yet Recruiting

A Study of CD19 UCAR-T Cells in Subjects With Autoimmune Diseases

NCT06294236Phase 1Active Not Recruiting

Study Evaluating SC291 in Subjects With Severe r/r B-cell Mediated Autoimmune Diseases (GLEAM)

NCT05732402Phase 1Active Not Recruiting

An Open-label Study of Povetacicept in Autoantibody-Associated Glomerular Diseases

NCT06978647Phase 1Recruiting

A Clinical Study of YTS109 Cell in R/R Autoimmune Diseases

NCT06226662Phase 2Not Yet RecruitingPrimary

Study of NM8074 in Patients with Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis (AAV)

NCT04871191Phase 3Not Yet Recruiting

Study of Salvage Therapy to Treat Patients with Granulomatosis with Polyangiitis

NCT06350110Phase 1Recruiting

Fourth-gen CAR T Cells Targeting BCMA/CD19 for Refractory Systemic Lupus Erythematosus (SLE)

NCT06379646Not ApplicableRecruiting

An Clinical Study of YTS109 Cell Injection in Subjects With Recurrent/Refractory Autoimmune Disease

NCT04413149Completed

Anti-neutrophil Cytoplasmic Antibody in Interstitial Lung Disease.

NCT06316076Phase 1Recruiting

Safety and Efficacy Study of CD19-CAR-DNT Cells in Autoimmune Diseases

Scroll to load more

Research Network

Activity Timeline